Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.42 |
| ▸ | CDC25B | P30305 | 5/20 | 0.42 |
| ▸ | ACP1 | P24666 | 4/20 | 0.42 |
| ▸ | PRKCA | P17252 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21428296 | 0.92 | KMT2A (0.41) | SIRT2PTPN1CDC25BACP1PRKCA | |
| SCHEMBL5708886 | 0.84 | PTPN1 (0.33) | SIRT2PTPN1CDC25BACP1CYP1A2 | |
| SCHEMBL8106856 | 0.82 | SIRT2 (0.45) | SIRT2PTPN1CDC25BACP1PRKCA | |
| SCHEMBL8105861 | 0.82 | SIRT2 (0.45) | SIRT2PTPN1CDC25BACP1PRKCA | |
| SCHEMBL8120957 | 0.82 | SIRT2 (0.45) | SIRT2PTPN1CDC25BACP1PRKCA | |
| SCHEMBL17064150 | 0.81 | MMP2 (0.44) | PTPN1CDC25BACP1PRKCACYP1A2 | |
| SCHEMBL8113804 | 0.80 | SIRT2 (0.42) | SIRT2PTPN1CDC25BACP1PRKCA | |
| SCHEMBL5924306 | 0.78 | SIRT2 (0.42) | SIRT2PTPN1CDC25BACP1PRKCA | |
| SCHEMBL21415447 | 0.76 | PTPN1 (0.45) | SIRT2PTPN1CDC25BACP1CYP1A2 | |
| SCHEMBL8053864 | 0.74 | PTPN1 (0.42) | PTPN1CDC25BACP1ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112094259-B | Iodine (III) -mediated radiofluorination | 通用医疗公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-112094259-A | Iodine (III) -mediated radiofluorination | 通用医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-106458960-B | Iodine (III) -mediated radiofluorination | 通用医疗公司 | 2020-10-23 | — | — | CN | disclosed |
| EP-3114117-B1 | IODINE(III)-MEDIATED RADIOFLUORINATION | MASSACHUSETTS GEN HOSPITAL (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3114117-B1 | IODINE(III)-MEDIATED RADIOFLUORINATION | MASSACHUSETTS GEN HOSPITAL (US) | 2019-10-02 | — | — | EP | disclosed |
| US-9957231-B2 | Iodine(II)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957231-B2 | Iodine(II)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957231-B2 | Iodine(II)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3114117-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | The General Hospital Corporation (US) | 2017-01-11 | — | — | EP | disclosed |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2015134923-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134923-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | TPO, FLI1, SSTR3 | SIRT2 957/4885PTPN1 4030/4885CDC25B 4194/4885 |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | TPO, FLI1, SSTR3 | SIRT2 957/4885PTPN1 4030/4885CDC25B 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.